Neoarsphenamine

Jump to: navigation, search

WikiDoc Resources for Neoarsphenamine

Articles

Most recent articles on Neoarsphenamine

Most cited articles on Neoarsphenamine

Review articles on Neoarsphenamine

Articles on Neoarsphenamine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Neoarsphenamine

Images of Neoarsphenamine

Photos of Neoarsphenamine

Podcasts & MP3s on Neoarsphenamine

Videos on Neoarsphenamine

Evidence Based Medicine

Cochrane Collaboration on Neoarsphenamine

Bandolier on Neoarsphenamine

TRIP on Neoarsphenamine

Clinical Trials

Ongoing Trials on Neoarsphenamine at Clinical Trials.gov

Trial results on Neoarsphenamine

Clinical Trials on Neoarsphenamine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Neoarsphenamine

NICE Guidance on Neoarsphenamine

NHS PRODIGY Guidance

FDA on Neoarsphenamine

CDC on Neoarsphenamine

Books

Books on Neoarsphenamine

News

Neoarsphenamine in the news

Be alerted to news on Neoarsphenamine

News trends on Neoarsphenamine

Commentary

Blogs on Neoarsphenamine

Definitions

Definitions of Neoarsphenamine

Patient Resources / Community

Patient resources on Neoarsphenamine

Discussion groups on Neoarsphenamine

Patient Handouts on Neoarsphenamine

Directions to Hospitals Treating Neoarsphenamine

Risk calculators and risk factors for Neoarsphenamine

Healthcare Provider Resources

Symptoms of Neoarsphenamine

Causes & Risk Factors for Neoarsphenamine

Diagnostic studies for Neoarsphenamine

Treatment of Neoarsphenamine

Continuing Medical Education (CME)

CME Programs on Neoarsphenamine

International

Neoarsphenamine en Espanol

Neoarsphenamine en Francais

Business

Neoarsphenamine in the Marketplace

Patents on Neoarsphenamine

Experimental / Informatics

List of terms related to Neoarsphenamine


Template:Chembox E number
Neoarsphenamine
Names
Other names
Identifiers
3D model (JSmol)
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
C13H13As2N2NaO4S
Molar mass 466.152
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Neosalvarsan is a synthetic chemotherapeutic that is an organoarsenic compound. It became available in 1912 and superseded the more toxic and less water-soluble salvarsan as an effective treatment for syphilis. Because both of these arsenicals carried considerable risk of side-effects, they were replaced for this indication by penicillin in the 1940s.

Both salvarsan and neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications.[1] This scheme is the basis for most modern pharmaceutical research. Both salvarsan and neosalvarsan are prodrugs, that is to say that they are metabolised to the active drug in the body.

Structure

The structure of Salvarsan, and presumably this derivative, was once believed to feature an As=As bond as shown in the figure.. In 2005, Salvarsan was shown to be a mixture of the cyclic trimer and a pentamer.[2][3] The revised structure features As-As single bonds, not double bonds.

References

  1. Strebhardt K, Ullrich A (2008). "Paul Ehrlich's magic bullet concept: 100 years of progress". Nat. Rev. Cancer. 8: 473. doi:10.1038/nrc2394. PMID 18469827. Unknown parameter |month= ignored (help)
  2. "accsnet.ne.jp". Retrieved 2007-08-25.
  3. Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS (2005). "The composition of Ehrlich's salvarsan: resolution of a century-old debate". Angewandte Chemie International Edition in English. 44 (6): 941–4. doi:10.1002/anie.200461471. PMID 15624113.


ar:نيوسالفارسان



Linked-in.jpg